PT - JOURNAL ARTICLE AU - Patterson, J. AU - Cleary, S. AU - van Zyl, H. AU - Awine, T. AU - Mayet, S. AU - Norman, J. AU - Kagina, B. M. AU - Muloiwa, R. AU - Hussey, G. D. AU - Silal, S. P. AU - , TI - Modelling the cost-effectiveness of hepatitis A vaccination in South Africa AID - 10.1101/2022.10.03.22280656 DP - 2022 Jan 01 TA - medRxiv PG - 2022.10.03.22280656 4099 - http://medrxiv.org/content/early/2022/10/05/2022.10.03.22280656.short 4100 - http://medrxiv.org/content/early/2022/10/05/2022.10.03.22280656.full AB - The World Health Organization (WHO) recommends the consideration of introducing routine hepatitis A vaccination into national immunization schedules for children ≥ 1 years old in countries with intermediate HAV endemicity. Recent data suggest that South Africa is transitioning from high to intermediate HAV endemicity, thus it is important to consider the impact and cost of potential routine hepatitis A vaccination strategies in the country.An age-structured compartmental model of hepatitis A transmission was calibrated with available data from South Africa, incorporating direct costs of hepatitis A treatment and vaccination. We used the calibrated model to evaluate the impact and costs of several childhood hepatitis A vaccination scenarios from 2023 to 2030. We assessed how each scenario impacted the burden of hepatitis A (symptomatic hepatitis A cases and mortality) as well as calculated the incremental cost per DALY averted as compared to the South African cost-effectiveness threshold. All costs and outcomes were discounted at 5%.For the modelled scenarios, the median estimated cost of the different vaccination strategies ranged from $1.71 billion to $2.85 billion over the period of 2023 to 2030, with the cost increasing for each successive scenario and approximately 39-52% of costs being due to vaccination. Scenario 1, which represented the administration of one dose of the hepatitis A vaccine in children < 2 years old, requires approximately 5.3 million vaccine doses over 2023-2030 and is projected to avert a total of 136,042 symptomatic cases [IQR: 88,842-221,483] and 31,106 [IQR: 22,975-36,742] deaths due to hepatitis A over the period of 2023 to 2030. The model projects that Scenario 1 would avert 8,741 DALYs over the period of 2023 to 2030, however is not cost-effective against the South African cost-effectiveness threshold with an ICER per DALY averted of $21,006. While Scenario 3 and 4 included the administration of more vaccine doses and averted more symptomatic cases of hepatitis A, these scenarios were absolutely dominated owing to the population being infected before vaccination through the mass campaigns at older ages.The model was highly sensitivity to varying access to liver transplant in South Africa. When increasing the access to liver transplant to 100% for baseline and Scenario 1, the ICER for Scenario 1 becomes cost-effective against the CET (ICER = $2,425). Given these findings, we recommend further research is conducted to understand the access to liver transplants in South Africa to better estimate the cost of liver transplant care for hepatitis A patients. The modelling presented in this paper has been used to develop a user-friendly application for vaccine policy makers to further interrogate the model outcomes and consider the costs and benefits of introducing routine hepatitis A vaccination in South Africa.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Vaccines for Africa Initiative (VACFA) received an unconditional grant from Sanofi Pasteur for capacity development. The funding covered costs for the research and dissemination of the results, including publications. Sanofi Pasteur did not have any input on the design and/or conduct of this study nor the interpretation of the results. Additional funding for this research was provided and the Department of Science and Innovation and the National Research Foundation (NRF). Any opinion, finding, and conclusion or recommendation expressed in this material is that of the authors and the NRF does not accept any liability in this regard.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the use of this data was obtained from the University of Cape Town Human Research Ethics Committee and the National Institute of Communicable Diseases (NICD).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.